FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1840902543> ?p ?o ?g. }

• W1840902543 endingPage "205" @default.
• W1840902543 startingPage "196" @default.
• W1840902543 abstract "A complete pathologic response to induction chemo-radiotherapy (CRT) has been identified as a favorable prognostic factor for patients with loco-regionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastro-esophageal junction (E/GEJ). Nodal involvement at the time of surgery has been found to be prognostically unfavorable. Less is known, however, about the prognostic import of less than complete pathologic regression and its relationship to residual nodal disease after induction chemotherapy.Between February 2008 and January 2012, 60 evaluable patients with ACA of the E/GEJ enrolled in a phase II trial of induction chemotherapy, surgery, and post-operative CRT. Eligibility required a clinical stage of T3-T4 or N1 or M1a (AJCC 6(th)). Induction chemotherapy with epirubicin 50 mg/m(2) d1, oxaliplatin 130 mg/m(2) d1, and fluorouracil 200 mg/m(2)/day continuous infusion for 3 weeks, was given every 21 days for three courses and was followed by surgical resection. Adjuvant CRT consisted of 50-55 Gy at 1.8-2.0 Gy/d and two courses of cisplatin (20 mg/m(2)/d) and fluorouracil (1,000 mg/m(2)/d) over 4 days during weeks 1 and 4 of radiotherapy. Residual viability (RV) was defined as the amount of remaining tumor in relation to acellular mucin pools and scarring.Of the 60 evaluable patients, 54 completed induction therapy and underwent curative intent surgery. The Kaplan-Meier projected 3-year overall survival (OS) for patients with pathologic N0 (n=20), N1 (n=12), N2 (n=13), and N3 (n=9) disease is 73%, 57%, 35%, and 0% respectively (P<0.001). The Kaplan-Meier projected 3-year OS of patients with low (0-25%, n=19), intermediate (26-75%, n=26), and high (>75%, n=9) residual tumor viability was 67%, 42%, and 17% respectively (P=0.004). On multivariable analysis (MVA), both the pN descriptor and RV were independently prognostic for OS. In patients with less nodal dissemination (N0/N1), RV was prognostic for OS [3-year OS 85% (0-25% viable) vs. 51% (>25% viable), P=0.028]. Outcomes were poor, however, for patients with advanced nodal disease (N2/N3) regardless of RV [3-year OS 20% (0-25% viable) vs. 21% (>25% viable), P=0.55].RV and the pN descriptor after induction chemotherapy are independent pathologic prognostic factors for OS in patients with LRA ACA of the E/GEJ. Patients with extensive nodal disease, however, have poor outcomes irrespective of residual tumor viability." @default.
• W1840902543 created "2016-06-24" @default.
• W1840902543 creator A5010850811 @default.
• W1840902543 creator A5020404499 @default.
• W1840902543 creator A5020860800 @default.
• W1840902543 creator A5031788305 @default.
• W1840902543 creator A5032876456 @default.
• W1840902543 creator A5034980758 @default.
• W1840902543 creator A5046052708 @default.
• W1840902543 creator A5049051306 @default.
• W1840902543 creator A5063411006 @default.
• W1840902543 creator A5065605420 @default.
• W1840902543 creator A5073148665 @default.
• W1840902543 creator A5077718869 @default.
• W1840902543 creator A5089048223 @default.
• W1840902543 date "2016-04-01" @default.
• W1840902543 modified "2023-10-16" @default.
• W1840902543 title "The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen." @default.
• W1840902543 cites W1980465361 @default.
• W1840902543 cites W1993369072 @default.
• W1840902543 cites W2013835366 @default.
• W1840902543 cites W2026613554 @default.
• W1840902543 cites W2026986976 @default.
• W1840902543 cites W2043570387 @default.
• W1840902543 cites W2054305985 @default.
• W1840902543 cites W2055631922 @default.
• W1840902543 cites W2058589751 @default.
• W1840902543 cites W2059562809 @default.
• W1840902543 cites W2065529539 @default.
• W1840902543 cites W2066292153 @default.
• W1840902543 cites W2068504442 @default.
• W1840902543 cites W2078399076 @default.
• W1840902543 cites W2079812570 @default.
• W1840902543 cites W2086679999 @default.
• W1840902543 cites W2111674123 @default.
• W1840902543 cites W2115072149 @default.
• W1840902543 cites W2122352172 @default.
• W1840902543 cites W2124204441 @default.
• W1840902543 cites W2124882723 @default.
• W1840902543 cites W2137696504 @default.
• W1840902543 cites W2141666552 @default.
• W1840902543 cites W2146834306 @default.
• W1840902543 cites W2154444715 @default.
• W1840902543 cites W2161395451 @default.
• W1840902543 cites W2169906597 @default.
• W1840902543 cites W2333224485 @default.
• W1840902543 cites W2338880854 @default.
• W1840902543 doi "https://doi.org/10.3978/j.issn.2078-6891.2015.097" @default.
• W1840902543 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4783752" @default.
• W1840902543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27034786" @default.
• W1840902543 hasPublicationYear "2016" @default.
• W1840902543 type Work @default.
• W1840902543 sameAs 1840902543 @default.
• W1840902543 citedByCount "2" @default.
• W1840902543 countsByYear W18409025432018 @default.
• W1840902543 countsByYear W18409025432020 @default.
• W1840902543 crossrefType "journal-article" @default.
• W1840902543 hasAuthorship W1840902543A5010850811 @default.
• W1840902543 hasAuthorship W1840902543A5020404499 @default.
• W1840902543 hasAuthorship W1840902543A5020860800 @default.
• W1840902543 hasAuthorship W1840902543A5031788305 @default.
• W1840902543 hasAuthorship W1840902543A5032876456 @default.
• W1840902543 hasAuthorship W1840902543A5034980758 @default.
• W1840902543 hasAuthorship W1840902543A5046052708 @default.
• W1840902543 hasAuthorship W1840902543A5049051306 @default.
• W1840902543 hasAuthorship W1840902543A5063411006 @default.
• W1840902543 hasAuthorship W1840902543A5065605420 @default.
• W1840902543 hasAuthorship W1840902543A5073148665 @default.
• W1840902543 hasAuthorship W1840902543A5077718869 @default.
• W1840902543 hasAuthorship W1840902543A5089048223 @default.
• W1840902543 hasConcept C121608353 @default.
• W1840902543 hasConcept C126322002 @default.
• W1840902543 hasConcept C141071460 @default.
• W1840902543 hasConcept C2776611710 @default.
• W1840902543 hasConcept C2776694085 @default.
• W1840902543 hasConcept C2776755627 @default.
• W1840902543 hasConcept C2777819096 @default.
• W1840902543 hasConcept C2780835546 @default.
• W1840902543 hasConcept C2780962732 @default.
• W1840902543 hasConcept C2781182431 @default.
• W1840902543 hasConcept C2781413609 @default.
• W1840902543 hasConcept C509974204 @default.
• W1840902543 hasConcept C526805850 @default.
• W1840902543 hasConcept C71924100 @default.
• W1840902543 hasConcept C90924648 @default.
• W1840902543 hasConceptScore W1840902543C121608353 @default.
• W1840902543 hasConceptScore W1840902543C126322002 @default.
• W1840902543 hasConceptScore W1840902543C141071460 @default.
• W1840902543 hasConceptScore W1840902543C2776611710 @default.
• W1840902543 hasConceptScore W1840902543C2776694085 @default.
• W1840902543 hasConceptScore W1840902543C2776755627 @default.
• W1840902543 hasConceptScore W1840902543C2777819096 @default.
• W1840902543 hasConceptScore W1840902543C2780835546 @default.
• W1840902543 hasConceptScore W1840902543C2780962732 @default.
• W1840902543 hasConceptScore W1840902543C2781182431 @default.
• W1840902543 hasConceptScore W1840902543C2781413609 @default.
• W1840902543 hasConceptScore W1840902543C509974204 @default.
• W1840902543 hasConceptScore W1840902543C526805850 @default.

• next